An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis

NCT ID: NCT03943147

Last Updated: 2022-10-17

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-07-15

Study Completion Date

2021-09-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety and effectiveness of BMS-986165 compared with placebo with regard to measures of kidney function in participants with lupus nephritis (LN).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lupus Nephritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors
Double-blind Study

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BMS-986165 Dose 1

Specified Dose on Specified Days

Group Type EXPERIMENTAL

BMS-986165

Intervention Type DRUG

Specified dose on specified days

Mycophenolate Mofetil

Intervention Type DRUG

Specified dose on specified days

BMS-986165 Dose 2

Specified Dose on Specified Days

Group Type EXPERIMENTAL

BMS-986165

Intervention Type DRUG

Specified dose on specified days

Mycophenolate Mofetil

Intervention Type DRUG

Specified dose on specified days

Placebo for BMS-986165

Specified Dose on Specified Days

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Specified dose on specified days

Mycophenolate Mofetil

Intervention Type DRUG

Specified dose on specified days

Mycophenolate Mofetil (MMF)

Specified Dose on Specified Days

Group Type EXPERIMENTAL

Mycophenolate Mofetil

Intervention Type DRUG

Specified dose on specified days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BMS-986165

Specified dose on specified days

Intervention Type DRUG

Placebo

Specified dose on specified days

Intervention Type DRUG

Mycophenolate Mofetil

Specified dose on specified days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Meets the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) criteria for Systemic Lupus Erythematosus (SLE)
* Renal biopsy confirming a histologic diagnosis of active Lupus Nephritis (LN) International Scociety of Nephrology/Renal Pathology Society (ISN/RPS) Classes III, IV-S, or IV-G; or Class V
* Urine protein:creatinine ratio (UPCR) ≥1.5 mg/mg or UPCR ≥1 mg/mg assessed with a 24-hour urine specimen

Exclusion Criteria

* Pure ISN/RPS Class V membranous LN
* Screening estimated glomerular filtration rate ≤30 mL/min/1.73 m\^2
* Dialysis within 12 months before screening or plans for dialysis within 6 months after enrollment in the study
* End-stage renal disease
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bristol-Myers Squibb

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bristol-Myers Squibb

Role: STUDY_DIRECTOR

Bristol-Myers Squibb

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama at Birmingham

Birmingham, Alabama, United States

Site Status

The Nephrology Group

Fresno, California, United States

Site Status

The Regents of The University of California

Los Angeles, California, United States

Site Status

University of Colorado School of Medicine

Aurora, Colorado, United States

Site Status

Local Institution - 0029

Gainesville, Florida, United States

Site Status

Emory University

Atlanta, Georgia, United States

Site Status

Augusta University

Augusta, Georgia, United States

Site Status

Atlanta Nephrology Referral Center

Lawrenceville, Georgia, United States

Site Status

Northwestern Medical Faculty Foundation

Chicago, Illinois, United States

Site Status

The University of Chicago Medicine

Chicago, Illinois, United States

Site Status

Nephrology Associates of Northern Illinois and Indiana - Fort Wayne

Fort Wayne, Indiana, United States

Site Status

Johns Hopkins University, Office of Research Administration

Baltimore, Maryland, United States

Site Status

Renal and Transplant Associates of New England, PC

Springfield, Massachusetts, United States

Site Status

Brighton Center for Specialty Care

Brighton, Michigan, United States

Site Status

Clinical Research Consultants - Kansas City

Kansas City, Missouri, United States

Site Status

Washington University School of Medicine

St Louis, Missouri, United States

Site Status

Rutgers New Jersey Medical School

Newark, New Jersey, United States

Site Status

Institute for Rheumatic and Autoimmune Diseases

Summit, New Jersey, United States

Site Status

NewYork-Presbyterian Queens

Fresh Meadows, New York, United States

Site Status

Northwell Health Physician Partners at Great Neck

Great Neck, New York, United States

Site Status

Local Institution - 0039

New York, New York, United States

Site Status

Icahn School of Medicine at Mount Sinai

New York, New York, United States

Site Status

Columbia University Medical Center

New York, New York, United States

Site Status

State University of New York Upstate Medical University

Syracuse, New York, United States

Site Status

East Carolina University Physicians

Greenville, North Carolina, United States

Site Status

Ohio State University, Wexner Medical Center

Columbus, Ohio, United States

Site Status

Local Institution - 0066

Oklahoma City, Oklahoma, United States

Site Status

Northeast Clinical Research Center

Bethlehem, Pennsylvania, United States

Site Status

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Site Status

Temple University Hospital

Philadelphia, Pennsylvania, United States

Site Status

Rhode Island Hospital

Providence, Rhode Island, United States

Site Status

Local Institution - 0030

Charleston, South Carolina, United States

Site Status

Office of Ramesh C. Gupta, MD

Memphis, Tennessee, United States

Site Status

Nephrotex Research Group

Dallas, Texas, United States

Site Status

Dallas Nephrology Associates - North Office

Dallas, Texas, United States

Site Status

El Paso Medical Research Institute

El Paso, Texas, United States

Site Status

The University of Texas Health Science Center at Houston

Houston, Texas, United States

Site Status

University of Utah

Salt Lake City, Utah, United States

Site Status

Virginia Mason Medical Center

Seattle, Washington, United States

Site Status

University of Washington School of Medicine

Seattle, Washington, United States

Site Status

Liverpool Hospital

Liverpool, New South Wales, Australia

Site Status

Sir Charles Gairdner Hospital

Nedlands, Western Australia, Australia

Site Status

Universitair Ziekenhuis Leuven

Leuven, , Belgium

Site Status

Centre Hospitalier Universitaire de Liege Site Sart Tilman

Liège, , Belgium

Site Status

Sheldon M. Chumir Health Center

Calgary, Alberta, Canada

Site Status

Toronto Western Hospital

Toronto, Ontario, Canada

Site Status

Centre Hospitalier Universitaire de Quebec Hospital Centre Hospitalier de IUniversite Laval

Québec, Quebec, Canada

Site Status

Local Institution

Guangzhou, Guangdong, China

Site Status

Local Institution

Xi'an, Shan3xi, China

Site Status

Vseobecna Fakultni Nemocnice v Praze

Prague, , Czechia

Site Status

Revmatologicky Ustav

Prague, , Czechia

Site Status

Universitaetsklinikum Essen

Essen, , Germany

Site Status

Medizinische Hochschule Hannover

Hanover, , Germany

Site Status

Universitatsmedizin der Johannes Gutenberg Universitat Mainz

Mainz, , Germany

Site Status

Local Institution

Haifa, , Israel

Site Status

Local Institution

Kfar Saba, , Israel

Site Status

Local Institution

Tel Aviv, , Israel

Site Status

Azienda SocioSanitaria Territoriale Fatebenefratelli Sacco

Milan, , Italy

Site Status

Local Institution - 0082

Milan, , Italy

Site Status

Universita degli Studi di Napoli Federico II

Napo, , Italy

Site Status

Istituto Scientifico di Pavia

Pavia, , Italy

Site Status

Morales Vargas Centro de Investigacion

León, Guanajuato, Mexico

Site Status

Centro Integral de Reumatologia

Guadalajara, Jalisco, Mexico

Site Status

Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V.

Zapopan, Jalisco, Mexico

Site Status

Unidad de Investigacion de las Enfermedades Reumaticas

Mexico City, Mexico City, Mexico

Site Status

Local Institution - 0094

Mexico City, Mexico City, Mexico

Site Status

Servicios Hospitalarios de Mexico

Chihuahua City, , Mexico

Site Status

Centro de Atencion e Investigacion Cardiovascular del Potosi

San Luis Potosí City, , Mexico

Site Status

Hospital Central Doctor Ignacio Morones Prieto

San Luis Potosí City, , Mexico

Site Status

Maastricht University Medical Centre

Maastricht, , Netherlands

Site Status

Erasmus Medisch Centrum

Rotterdam, , Netherlands

Site Status

Medical Center

Kemerovo, , Russia

Site Status

City Clinical Hospital #15 named after O.M. Filatova

Moscow, , Russia

Site Status

V.A. Nasonova Research Rheumatology Institute

Moscow, , Russia

Site Status

Local Institution - 0015

Saratov, , Russia

Site Status

Local Institution

Busan, , South Korea

Site Status

Local Institution - 0071

Daejeon, , South Korea

Site Status

Local Institution - 0090

Gwangju, , South Korea

Site Status

Local Institution - 0056

Seoul, , South Korea

Site Status

Local Institution

Seoul, , South Korea

Site Status

Local Institution

Seoul, , South Korea

Site Status

Local Institution

Seoul, , South Korea

Site Status

Local Institution

Suwon, , South Korea

Site Status

Fundacio Puigvert

Barcelona, , Spain

Site Status

Hospital Universitari Vall dHebron

Barcelona, , Spain

Site Status

Hospital Clinic de Barcelona

Barcelona, , Spain

Site Status

Hospital Universitario 12 de Octubre

Madrid, , Spain

Site Status

Hospital Regional Universitario de Malaga Hospital General

Málaga, , Spain

Site Status

Hospital Universitario Nuestra Senora de Valme

Seville, , Spain

Site Status

Local Institution

Hualien City, , Taiwan

Site Status

Local Institution

Kaohsiung City, , Taiwan

Site Status

Local Institution

Taichung, , Taiwan

Site Status

Local Institution - 0037

Tainan City, , Taiwan

Site Status

Local Institution

Taipei, , Taiwan

Site Status

Brighton and Sussex University Hospitals NHS Trust

Brighton, , United Kingdom

Site Status

Cambridge University Hospitals NHS Foundation Trust

Cambridge, , United Kingdom

Site Status

University Hospitals of Leicester NHS Trust

Leicester, , United Kingdom

Site Status

Barts Health NHS Trust

London, , United Kingdom

Site Status

Manchester University NHS Foundation Trust

Manchester, , United Kingdom

Site Status

Epsom and Saint Helier University Hospitals NHS Trust

Surrey, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Belgium Canada China Czechia Germany Israel Italy Mexico Netherlands Russia South Korea Spain Taiwan United Kingdom

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2018-004142-42

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

IM011-073

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.